Ghost probiotics with a combined regimen: a novel therapeutic approach against the Zika virus, an emerging world threat

Critical Reviews in Biotechnology

Volumn 38, Issue 3, 2018, Pages 438-454

  Bajpai, Vivek K ^a   Chandra, Vishal ^b,c   Kim, Na Hyung ^d   Rai, Rajni ^a   Kumar, Pradeep ^a,i   Kim, Kangmin ^e   Aeron, Abhinav ^e   Kang, Sun Chul ^f   Maheshwari, D K ^g   Na, MinKyun ^h   Rather, Irfan A ^a   Park, Yong Ha ^a  

^a Yeungnam University   (South Korea)

^b INTEGRAL UNIVERSITY   (India)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^d Wonkwang University   (South Korea)

^e Chonbuk National University   (South Korea)

^f Daegu University   (South Korea)

^g GURUKUL KANGRI UNIVERSITY   (India)

^h Chungnam National University   (South Korea)

ⁱ NORTH EASTERN REGIONAL INSTITUTE OF SCIENCE AND TECHNOLOGY   (India)

Author keywords

phytoconstituents; plants; probiotic peptides; probiotics; viral infection; Zika virus

Indexed keywords

EPIDEMIOLOGY;

BIOLOGICAL RESPONSE MODIFIERS; CLINICAL MANIFESTATION; HEALTH BENEFICIAL EFFECTS; PHYTOCONSTITUENTS; PLANTS; PREVENTIVE STRATEGIES; PROBIOTICS; VIRAL INFECTIONS;

VIRUSES;

ANTIHISTAMINIC AGENT; DIPYRONE; HERBACEOUS AGENT; PROBIOTIC AGENT; PHYTOCHEMICAL;

ANTIVIRAL ACTIVITY; CLINICAL FEATURE; CONGENITAL MALFORMATION; DRUG FORMULATION; HOST PATHOGEN INTERACTION; HUMAN; MOSQUITO BITE; NONHUMAN; PLANT; PRIORITY JOURNAL; REVIEW; SEXUAL TRANSMISSION; VIRUS ATTACHMENT; VIRUS ENVELOPE; VIRUS TRANSMISSION; VIRUS VIRULENCE; ZIKA FEVER; ZIKA VIRUS; ANIMAL; DRUG EFFECT; TRANSMISSION; VIRUS ENTRY;

ANIMALS; HUMANS; PHYTOCHEMICALS; PROBIOTICS; VIRUS INTERNALIZATION; ZIKA VIRUS; ZIKA VIRUS INFECTION;

EID: 85044021812     PISSN: 07388551     EISSN: 15497801     Source Type: Journal    
DOI: 10.1080/07388551.2017.1368445     Document Type: Review

References (159)

1. Chen HL, Tang RB., Why Zika virus infection has become a public health concern? J Chin Med Assoc. 2016;79:174–178.
2. Mansuy JM, Dutertre M, Mengelle C, et al. Zika virus: high infectious viral load in semen, a new sexually transmitted pathogen? Lancet Infect Dis. 2016;16:405.
3. Krauer F, Riesen M, Reveiz L, et al. Zika virus infection as a cause of congenital brain abnormalities and guillain-barré syndrome: systematic review. PLoS Med. 2017;14:e1002203.
4. Cugola FR, Fernandes IR, Russo FB, et al. The Brazilian Zika virus strain causes birth defects in experimental models. Nature. 2016;534:267–271.
5. Wu KY, Zuo GL, Li XF, et al. Vertical transmission of Zika virus targeting the radial glial cells affects cortex development of offspring mice. Cell Res. 2016;26:645–654.
6. Triunfol M., A new mosquito-borne threat to pregnant women in Brazil. Lancet Infect Dis. 2016;16:156–157.
7. Duffy MR, Chen TH, Hancock WT, et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. N Engl J Med. 2009;360:2536–2543.
8. Musso D, Nilles EJ, Cao-Lormeau VM., Rapid spread of emerging Zika virus in the Pacific area. Clin Microbiol Infect. 2014;20:595–596.
9. Waltz E., GM mosquitoes fire first salvo against Zika virus. Nat Biotechnol. 2016;34:221–222.
10. BBC South Korea confirms first Zika case. Available from: http://www.bbc.com/news/world-asia-35868532, 2016.
11. Malone RW, Homan J, Callahan MV, et al. Zika Virus: Medical countermeasure development challenges. PLoS Negl Trop Dis. 2016;10(3):e0004530.
12. Bremel RD, Homan EJ., An integrated approach to epitope analysis II: a system for proteomic-scale prediction of immunological characteristics. Immunome Res. 2010;6:8.
13. Janies D, Treseder T, Alexandrov B, et al. The supramap project: linking pathogen genomes with geography to fight emergent infectious diseases. Cladistics. 2011;27:61–66.
14. Kirkpatrick BD, Whitehead SS, Pierce KK, et al. The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model. Sci Trans Med. 2016;8:330–336.
15. Hamel R, Liegeois F, Wichit S, et al. Zika virus: epidemiology, clinical features and host-virus interactions. Microbes Infect. 2016;18:441–449.
16. Besnard M, Lastere S, Teissier A, et al. Evidence of perinatal transmission of Zika virus, French Polynesia, December 2013 and February 2014. Euro Surveill. 2014;19:20751.
17. Zika virus: a new global threat for 2016. Lancet. 2014;383:764–766.
18. Dasgupta S, Reagan-Steiner S, Goodenough D, et al. Patterns in Zika virus testing and infection, by report of symptoms and pregnancy status–United States, January 3-March 5, 2016. Morb Mortal Wkly Rep. 2016;65:395–399.
19. Zwizwai R., Infection disease surveillance update. Lancet Infect Dis. 2016;16:157.
20. Kaddumukasa MA, Mutebi JP, Lutwama JJ, et al. Mosquitoes of Zika forest, Uganda: species composition and relative abundance. J Med Entomol. 2014;51:104–113.
21. Campos GS, Bandeira AC, Sardi SI., Zika virus outbreak, Bahia, Brazil. Emerging Infect Dis. 2015;21:1885–1886.
22. Calvet G, Aguiar RS, Melo ASO, et al. Detection and sequencing of Zika virus from amniotic fluid of fetuses with microcephaly in Brazil: a case study. Lancet Infect Dis. 2016;16(6):653–660.
23. Zanluca C, dos Santos CND., Zika virus–an overview. Microbes Infect. 2016;18:295–301.
24. Barzon L, Pacenti M, Berto A, et al. Isolation of infectious Zika virus from saliva and prolonged viral RNA shedding in a traveller returning from the Dominican Republic to Italy, January 2016. Euro Surveill. 2016;21:30159.
25. Gourinat AC, O'Connor O, Calvez E, et al. Detection of Zika virus in urine. Emerging Infect Dis. 2015;21:84–86.
26. Oliveira ASM, Malinger G, Ximenes R, et al. Zika virus intrauterine infection causes fetal brain abnormality and microcephaly: tip of the iceberg? Ultrasound Obstet Gynecol. 2016;47:6–7.
27. Martines RB, Bhatnagar J, Keating MK, et al. Evidence of Zika virus infection in brain and placental tissues from two congenitally infected newborns and two fetal losses - Brazil, 2015. Morb Mortal Wkly Rep. 2016;65:159–160.
28. Grard G, Caron M, Mombo IM, et al. Zika virus in Gabon (Central Africa)–2007: a new threat from Aedes albopictus? PLoS Negl Trop Dis. 2014;8:1–6.
29. Marchette NJ, Garcia R, Rudnick A., Isolation of Zika virus from Aedes aegypti mosquitoes in Malaysia. Am J Trop Med Hyg. 1969;18:411–415.
30. Olson JG, Ksiazek TG, Suhandiman, et al. Zika virus, a cause of fever in Central Java, Indonesia. Trans R Soc Trop Med Hyg. 1981;75:389–393.
31. Diallo D, Sall AA, Diagne CT, et al. Zika virus emergence in mosquitoes in southeastern Senegal, 2011. PLoS One. 2014;9:e109442.
32. Boorman JPT, Porterfield JS. A simple technique for infection of mosquitoes with viruses; transmission of Zika virus. Trans R Soc Trop Med Hyg. 1956;50:238–242.
33. Li MI, Wong PSJ, Ng LC, et al. Oral susceptibility of Singapore Aedes (Stegomyia) aegypti (Linnaeus) to Zika virus. PLOS Negl Trop Dis. 2012;6:e1792.
34. Musso D, Roche C, Robin E, et al. Potential sexual transmission of Zika virus. Emerging Infect Dis. 2015;21:359–361.
35. McCarthy M., Zika virus was transmitted by sexual contact in Texas, health officials report. BMJ. 2016;352:720.
36. Foy BD, Kobylinski KC, Chilson Foy JL, et al. Probable non-vector-borne transmission of Zika virus, Colorado, USA. Emerging Infect Dis. 2011;17:880–882.
37. Atkinson B, Hearn P, Afrough B, et al. Detection of Zika virus in semen. Emerging Infect Dis. 2016; 22:940.
38. Yockey LJ, Varela L, Rakib T, et al. Vaginal exposure to Zika virus during pregnancy leads to fetal brain infection. Cell. 2016;166:1247–1256.
39. Tang WW, Young MP, Mamidi A, et al. A mouse model of Zika virus sexual transmission and vaginal viral replication. Cell Rep. 2016;17:3091–3098.
40. Govero J, Esakky P, Scheaffer SM, et al. Zika virus infection damages the testes in mice. Nature. 2016;540:438–442.
41. Ma W, Li S, Ma S, et al. Zika virus causes testis damage and leads to male infertility in mice. Cell. 2017;168:e542.
42. Petersen LR, Jamieson DJ, Powers AM, et al. Zika virus. N Engl J Med. 2016;374:1552–1563.
43. Kleber de Oliveira W, Cortez-Escalante J, De Oliveira WT, et al. Increase in reported prevalence of microcephaly in infants born to women living in areas with confirmed Zika virus transmission during the first trimester of pregnancy–Brazil, 2015. MMWR Morb Mortal Wkly Rep. 2016;65:242–247.
44. Cauchemez S, Besnard M, Bompard P, et al. Association between Zika virus and microcephaly in French Polynesia, 2013-15: a retrospective study. Lancet. 2016;387:2125–2132.
45. O’Leary DR, Kuhn S, Kniss KL, et al. Birth outcomes following West Nile virus infection of pregnant women in the United States: 2003–2004. Pediatrics. 2006;117:537–545.
46. Ioos S, Mallet HP, Goffart IL, et al. Current Zika virus epidemiology and recent epidemics. Med Mal Infect. 2014;44:302–307.
47. Li J, Xiong Y, Wu W, et al. Zika virus in a traveler returning to China from Caracas, Venezuela, February 2016. Emerging Infect Dis. 2016;22:1133–1136.
48. Nah K, Mizumoto K, Miyamatsu Y, et al. Estimating risks of importation and local transmission of Zika virus infection. Peer J. 2016;4:e1904.
49. Center for Disease Control and Prevention (CDC). Centers for Disease Control, R.O.C (Taiwan). As Zika outbreaks persist in Latin America, travelers visiting areas with active transmission urged to take precautions against mosquito bites, and seek immediate medical attention and inform physician of relevant travel history when experiencing symptoms within two weeks of their return. 2016. [cited 2016 Feb 11]. Available from: http://www.cdc.gov.tw/english/index.aspx.
50. Center for Disease Control and Prevention (CDC). Centers for Disease Control, R.O.C (Taiwan). People returning from Zika affected countries recommended to use condoms when having sex and postpone giving blood for at least 28 days to prevent Zika transmission. 2016. [cited 2016 Feb 11]. Available from: http://www.cdc.gov.tw/english/index.aspx.
51. Gould EA, de Lamballerie X, Zanotto PM, et al. Evolution, epidemiology, and dispersal of flaviviruses revealed by molecular phylogenies. Adv Virus Res. 2001;57:71–103.
52. Driggers RW, Ho CY, Korhonen EM, et al. Zika virus infection with prolonged maternal viremia and fetal brain abnormalities. N Eng J Med. 2016;374:2142–2151.
53. Mlakar J, Korva M, Tul N, et al. Zika virus associated with microcephaly. N Engl J Med. 2016;374:951–958.
54. Pan American Health Organization (PAHO). Zika virus infection. 2016. [cited 2016 Mar 2]. Available from: http://www.paho.org/hq/index.php?option¼com_content&view¼article&id¼11585&Itemid¼41688&lang¼en.
55. Oduyebo T, Petersen EE, Rasmussen SA, et al. Update: interim guidelines for health care providers caring for pregnant women and women of reproductive age with possible Zika virus exposure d United States, 2016. Morb Mortal Wkly Rep. 2016;65:122–127.
56. Staples JE, Dziuban EJ, Fischer M, et al. Interim guidelines for the evaluation and testing of infants with possible congenital Zika virus infection d United States, 2016. Morb Mortal Wkly Rep. 2016;65:63–67.
57. Center for Disease Control and Prevention (CDC). Zika virus. Fact sheets and posters-help control mosquitoes that spread Dengue, Chikungunya and Zika viruses. Last updated February 11, 2016. CDC USA; [cited 2016 Feb 11]. Available from: http://www.cdc.gov/zika/pdfs/control_mosquitoes_chikv_denv_zika.pdf. 2016c.
58. NBC News. 2016. Available from: http://www.nbcnews.com/storyline/zika-virus-outbreak/infected-mosquitoes-can-t-transmit-zika-virus-study-finds-n568261
59. Newsweek. 2016. Available from: http://www.newsweek.com/scientists-grow-mini-brains-figure-out-why-zika-causes-microcephaly-456723.
60. Perry ST, Buck MD, Plummer EM, et al. An iminosugar with potent inhibition of dengue virus infection in vivo. Antiviral Res. 2013;98:35–43.
61. Stavale EJ, Vu H, Sampath A, et al. In vivo therapeutic protection against influenza A (H1N1) oseltamivir-sensitive and resistant viruses by the iminosugar UV-4. PLoS One. 2015;18:e0121662.
62. Chang J, Block TM, Guo JT., Antiviral therapies targeting host ER alpha-glucosidases: current status and future directions. Antiviral Res. 2013;99:251–260.
63. Makhluf H, Kim K, Shresta S., Novel strategies for discovering inhibitors of Dengue and Zika fever. Expert Opin Drug Discov. 2016;11:921–923.
64. Ekins S, Mietchen D, Coffee M, et al. Open drug discovery for the Zika virus. F1000Res. 2016;5:150.
65. Xu M, Lee EM, Wen Z, et al. Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen. Nat Med. 2016;22:1101–1107.
66. Pomin VH., Sulfated glycans and related digestive enzymes in the Zika virus infectivity: Potential mechanisms of virus-host interaction and perspectives in Drug Discovery. Interdiscip Perspect Infect Dis. 2017;2017:e4894598.
67. Ming GL, Tang H, Song H., Advances in Zika virus research: stem cell models, challenges, and opportunities. Cell Stem Cell. 2016;19:690–702.
68. Saxena SK, Elahi A, Gadugu S, et al. Zika virus outbreak: an overview of the experimental therapeutics and treatment. Virusdisease. 2016;27:111–115.
69. Oliveira ER, Mohana-Borges R, de Alencastro RB, et al. The flavivirus capsid protein: structure, function and perspectives towards drug design. Virus Res. 2017;2:115–123.
70. Nandy A, Basak SC., A brief of computer-assisted approaches to rational design of peptide vaccines. Int J Mol Sci. 2016;17:e666.
71. Weaver SC, Costa F, Garcia-Blanco MA, et al. Zika virus: history, emergence, biology, and prospects for control. Antiviral Res. 2016;130:69–80.
72. Lim SP, Wang QY, Noble CG, et al. Ten years of dengue drug discovery: progress and prospects. Antiviral Res. 2013;100:500–519.
73. Clark MJ, Miduturu C, Schmidt AG, et al. GNF-2 inhibits dengue virus by targeting Abl kinases and the viral E protein. Cell Chem Biol. 2016;23:443–452.
74. Lehtoranta L, Pitkaranta A, Korpela R., Probiotics in respiratory virus infections. Eur J Clin Microbiol Infect Dis. 2014;33:1289–1302.
75. Vouloumanoua EK, Makrisa GC, Karageorgopoulosa DE, et al. Probiotics for the prevention of respiratory tract infections: a systematic review. Int J Antimicrob Agents. 2009;34:e197.
76. Zuppa AA, Alighieri G, Scorrano A, et al. Prebiotics and probiotics in infant nutrition. In: Ronald Ross W, Victor RP, editors. Probiotics, prebiotics, and synbiotics part ii-bioactive foods in health promotion. Boston: Academic Press. 2016. p. 441–477.
77. Taverniti V, Guglielmetti S., The immunomodulatory properties of probiotic microorganisms beyond their viability (ghost probiotics: proposal of paraprobiotic concept). Genes Nutr. 2011;6:261–274.
78. Dash G, Raman RP, Pani Prasad K, et al. Evaluation of paraprobiotic applicability of Lactobacillus plantarum in improving the immune response and disease protection in giant freshwater prawn, Macrobrachium rosenbergii (de Man, 1879). Fish Shellfish Immunol. 2015;43:167–174.
79. Millar M, Wilks M, Costeloe K., Probiotics for preterm neonates? Arch Dis Child Fetal Neonatal Ed. 2003;88:354–358.
80. Adams CA., The probiotic paradox: live and dead cells are biological response modifiers. Nutr Res Rev. 2010;23:37–46.
81. Strom K, Sjogren J, Broberg A, et al. Lactobacillus plantarum MiLAB 393 produces the antifungal cyclic dipeptides cyclo(L-Phe-L-Pro) and cyclo(LPhe- trans-4-OH-L-Pro) and 3-phenyllactic acid. Appl Environ Microbiol. 2002;68:4322–4327.
82. Pothoulakis C, Kelly CP, Joshi MA, et al. Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterol. 1993;104:1108–1115.
83. Nanno M, Ohwaki M, Mutai M., Induction by Lactobacillus casei of increase in macrophage colony-forming cells and serum colony-stimulating activity in mice. Japanese J Cancer Res. 1986;77:703–710.
84. Claud EC, Walker WA., Hypothesis: inappropriate colonization of the premature intestine can cause neonatal necrotizing enterocolitis. Faseb J. 2001;15:1398–1403.
85. Hoyos AB., Reduced incidence of necrotizing enterocolitis associated with enteral administration of Lactobacillus acidophilus and Bifidobacterium infantis to neonates in an intensive care unit. Int J Infect Dis. 1999;3:197–202.
86. Deshpande G, Rao S, Patole S. Probiotics for prevention of necrotising enterocolitis in preterm neonates with very low birthweight: a systematic review of randomised controlled trials. Lancet. 2007;369:1614–1620.
87. Costeloe K, Hardy P, Juszczak E, et al. Bifidobacterium breve BBG-001 in very preterm infants: a randomised controlled phase 3 trial. Lancet. 2016;13387:649–660.
88. Olivares M, Diaz-Ropero MP, Sierra S, et al. Oral intake of Lactobacillus fermentum CECT5716 enhances the effects of influenza vaccination. Nutrition. 2007;23:254–260.
89. Rizzardini G, Eskesen D, Calder PC, et al. Evaluation of the immune benefits of two probiotic strains Bifidobacterium animalis ssp. lactis, BB-12(R) and Lactobacillus paracasei ssp. paracasei, L. casei 431(R) in an influenza vaccination model: a randomized, double-blind, placebo-controlled study. Br J Nutr. 2012;107:876–884.
90. Waki N, Yajima N, Suganuma H, et al. Oral administration of Lactobacillus brevis KB290 to mice alleviates clinical symptoms following influenza virus infection. Lett Appl Microbiol. 2013;58:87–93.
91. Youn HN, Lee DH, Lee YN, et al. Intranasal administration of live Lactobacillus species facilitates protection against influenza virus infection in mice. Antiviral Res. 2012;93:138–143.
92. Harata G, He F, Hiruta N, et al. Intranasal administration of Lactobacillus rhamnosus GG protects mice from H1N1 influenza virus infection by regulating respiratory immune responses. Lett Appl Microbiol. 2010;50:597–602.
93. Fensterl V, Sen GC., Interferons and viral infections. Biofactors. 2009;35:14–20.
94. Izumo T, Maekawa T, Ida M, et al. Effect of intranasal administration of Lactobacillus pentosus S-PT84 on influenza virus infection in mice. Int Immunopharmacol. 2010;10:1101–1106.
95. Kawase M, He F, Kubota A, et al. Oral administration of Lactobacilli from human intestinal tract protects mice against influenza virus infection. Lett Appl Microbiol. 2010;51:6–10.
96. Kobayashi N, Saito T, Uematsu T, et al. Oral administration of heat-killed Lactobacillus pentosus strain b240 augment protection against influenza virus infection in mice. Int Immunopharmacol. 2011;11:199–203.
97. Maeda N, Nakamura R, Hirose Y, et al. Oral administration of heat-killed Lactobacillus plantarum L-137 enhances protection against influenza virus infection by stimulation of type I interferon production in mice. Int Immunopharmacol. 2009;9:1122–1125.
98. Bajpai VK, Han JH, Nam GJ, et al. Characterization and pharmacological potential of Lactobacillus sakei 1I1 isolated from fresh water fish Zacco koreanus. DARU J Pharm Sci. 2016;24:e8.
99. Rather IA, Choi KH, Bajpai VK, et al. Antiviral mode of action of Lactobacillus plantarum YML009 on influenza virus H1N1. Bangladesh J Pharmacol. 2015;10:475–482.
100. Shi SH, Yang WT, Yang GL, et al. Immunoprotection against influenza virus H9N2 by the oral administration of recombinant Lactobacillus plantarum NC8 expressing hemagglutinin in BALB/c mice. Virology. 2014;464:166–176.
101. Majumder R, Rather IA, Bajpai VK, et al. In vitro antiviral activity of Lactobacillus plantarum using SPF embryonated eggs and hemagglutination assay. Bangladesh J. Pharmacol. 2015;10:688–691.
102. Seo BJ, Rather IA, Kumar VJR, et al. Evaluation of Leuconostoc mesenteroides YML003 as a probiotic against low-pathogenic avian influenza (H9N2) virus in chickens. J Appl Microbiol. 2012;113:163–171.
103. Seo BJ, Mun MR, Kumar VJR, et al. Bile tolerant Lactobacillus reuteri isolated from pig feces inhibits enteric bacterial pathogens and porcine rotavirus. Vet Res Commun. 2010;34:323–333.
104. Musso D, Roche C, Nhan TX, et al. Detection of Zika virus in saliva. J Clin Virol. 2015;68:53–55.
105. Lee K, Park JE, Kim MJ, et al. Probiotic bacteria, B. longum and L. acidophilus inhibit infection by rotavirus in vitro and decrease the duration of diarrhea in pediatric patients. Clin Res Hepatol Gastroenterol. 2015;39:237–244.
106. nd Congress of Asian Pediatric Research Yokohama, Japan. 2007.
107. Comia-Capate C, Doloroso K., Revised Dengue Clinical Case Management Guidelines. Republic of the Philippines: Department of Health; 2011. p. 1–27.
108. Amalaradjou MAR, Bhunia AK., Bioengineered probiotics, a strategic approach to control enteric infections. Bioengineered. 2013;4:379–387.
109. Mousa HAL., Herbal therapies for prevention and treatment of influenza and influenza-like illness. J Infect Dis Ther. 2015;3:e215.
110. Tong XK, Qiu H, Zhang X, et al. WSS45, a sulfated alpha-d-glucan, strongly interferes with Dengue 2 virus infection in vitro. Acta Pharmacol Sin. 2010;31:585–592.
111. Han H, He W, Wang W, et al. Inhibitory effect of aqueous Dandelion extract on HIV-1 replication and reverse transcriptase activity. BMC Complement Altern Med. 2011;11:e112.
112. Mousa HA., Prevention and treatment of viral infections by natural therapies. J Prevent Infect Control. 2014;15:1–3.
113. Tang LI, Ling AP, Koh RY, et al. Screening of anti-dengue activity in methanolic extracts of medicinal plants. BMC Complement Altern Med. 2012;12:e3.
114. Rahman S, Salehin F, Iqbal A., In vitro antioxidant and anticancer activity of young Zingiber officinale against human breast carcinoma cell lines. BMC Complement Altern Med. 2011;11:e76.
115. Chiang LC, Chiang W, Liu MC, et al. In vitro antiviral activities of Caesalpinia pulcherrima and its related flavonoids. J Antimicrob Chemother. 2003;52:194–198.
116. Kiat TS, Pippen R, Yusof R, et al. Inhibitory activity of cyclohexenyl chalcone derivatives and flavonoids of finger root, Boesenbergia rotunda (L.), towards dengue-2 virus NS3 protease. Bioorg Med Chem Lett. 2006;16:3337–3340.
117. Jacob JR, Korba BE, You JE, et al. Korean medicinal plant extracts exhibit antiviral potency against viral hepatitis. J Altern Complement Med. 2004;10:1019–1026.
118. Zandi K, Teoh BT, Sam SS, et al. Novel antiviral activity of baicalein against dengue virus. BMC Complement Altern Med. 2012;12:e214.
119. Tian Y, Sun LM, Liu XQ, et al. Anti-HBV active flavone glucosides from Euphorbia humifusa Willd. Fitoterapia. 2010;81:799–802.
120. Evers DL, Chao CF, Wang X, et al. Human cytomegalovirus-inhibitory flavonoids: studies on antiviral activity and mechanism of action. Antiviral Res. 2005;68:124–134.
121. Zandi K, Teoh BT, Sam SS, et al. In vitro antiviral activity of fisetin, rutin and naringenin against dengue virus type-2. J Med Plants Res. 2011;5:5534–5539.
122. Zandi K, Teoh BT, Sam SS, et al. Antiviral activity of four types of bioflavonoid against dengue virus type-2. Virol J. 2011;8:e560.
123. Xu G, Dou J, Zhang L, et al. Inhibitory effects of baicalein on the influenza virus in vivo is determined by baicalin in the serum. Biol Pharm Bull. 2010;33:238–243.
124. Guo Q, Zhao L, You Q, et al. Anti-hepatitis B virus activity of wogonin in vitro and in vivo. Antiviral Res. 2007;74:16–24.
125. Muhamad M, Kee LY, Rahman NA, et al. Antiviral actions of flavanoid-derived compounds on dengue virus type-2. Int J Biol Sci. 2010;6:294–302.
126. Rehman S, Ashfaq UA, Riaz S, et al. Antiviral activity of Acacia nilotica against Hepatitis C virus in liver infected cells. Virol J. 2011;8:6:220.
127. Lin LT, Chung CY, Hsu WC, et al. Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entry. J Hepatol. 2015;62:541–548.
128. Chao KP, Hua KF, Hsu HY, et al. Anti-inflammatory activity of sugiol, a diterpene isolated from Calocedrus formosana bark. Planta Med. 2005;71:300–305.
129. Bajpai VK, Kim HR, Kang SC., In vitro anti-fungal activity of various hydroxylated fatty acids bioconverted by P. aeruginosa PR3. Agric Chem Biotechnol. 2006;49:131–134.
130. Bajpai VK, Sharma A, Kang SC, et al. Antioxidant, lipid peroxidation inhibition and free radical scavenging efficacy of a diterpenoid compound sugiol isolated from Metasequoia glyptostroboides. Asian Pac J Trop Med. 2014;7:9–15.
131. Bajpai VK, Kang SC., A diterpenoid sugiol from Metasequoia glyptostroboides with α-glucosidase and tyrosinase inhibitory potential. Bangladesh J Pharmacol. 2014;9:312–316.
132. Bajpai VK, Kim NH, Kim K, et al. Antiviral potential of a diterpenoid compound sugiol from Metasequoia glyptostroboides. Pak J Pharm Sci. 2016;29:1077–1080.
133. Benelli G, Pavela R, Canale A, et al. Tick repellents and acaricides of botanical origin: a green roadmap to control tick-borne diseases? Parasitol Res. 2016;115:2545–2560.
134. Pavela R, Vrchotova N, Triska J., Mosquitocidal activities of thyme oils (Thymus vulgaris L.) against Culex quinquefasciatus (Diptera: Culicidae). Parasitol Res. 2009;105:1365–1370.
135. Benelli G, Benvenuti S, Desneux N, et al. Cephalaria transsylvanica-based flower Strips as potential food source for bees during dry periods in European Mediterranean Basin countries. PLoS One. 2014;9:e93153.
136. Semmler M, Abdel-Ghaffar F, Schmidt J, et al. Evaluation of biological and chemical insect repellents and their potential adverse effects. Parasitol Res. 2014;113:185–188.
137. Ahmad N, Fazal H, Ayaz M, et al. Dengue fever treatment with Carica papaya leaves extracts. Asian Pac J Trop Biomed. 2011;1:330–333.
138. Otsuki N, Dang NH, Kumagai E, et al. Aqueous extract of Carica papaya leaves exhibits anti-tumor activity and immunomodulatory effects. J Ethnopharmacol. 2010;127:760–767.
139. Joseph B, Sankarganesh P, Ichiyama K, et al. In vitro study on cytotoxic effect and anti-DENV2 activity of Carica papaya L. leaf. Frontiers Life Sci. 2015;8:18–22.
140. Warfield KL, Plummer E, Alonzi DS, et al. A Novel iminosugar UV-12 with activity against the diverse viruses influenza and dengue (Novel iminosugar antiviral for influenza and dengue). Viruses. 2015;7:2404–2427.
141. Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it’s not just for mice anymore. Clin Infect Dis. 2007;44:79–86.
142. Kishimoto C, Crumpacker CS, Abelmann WH. Ribavirin treatment of murine coxsackievirus B3 myocarditis with analyses of lymphocyte subsets. J Am Coll Cardiol. 1988;12:1334–1341.
143. Kim MJ, Lee DK, Park JE, et al. Antiviral activity of Bifidobacterium adolescentis SPM1605 against Coxsackievirus B3. Biotechnol Equip. 2014;28:681–688.
144. Kitazato K, Wang Y, Kobayashi N., Viral infectious disease and natural products with antiviral activity. Drug Discov Ther. 2007;1:14–22.
145. Park YH, Lim JH, Seo BJ., Rice-fermented food composition containing a rice-sweetened liquid, fermented by means of Kimchi Lactobacillus, as an effective ingredient, and having antibacterial and antiviral effects. USA Patent. Probionic Co. Ltd., 2013; Patent # W02012153885 A9.
146. Bajpai VK, Kang SC, Park E, et al. Diverse role of microbially bioconverted product of cabbage (Brassica oleracea) by Pseudomonas syringe pv. T1 on inhibiting Candida species. Food Chem Toxicol. 2011;49:403–407.
147. Tsai SH, Liu CP, Yang SS., Microbial conversion of food wastes for biofertilizer production with thermophilic and lipophilic microbes. Renew Energy. 2007;32:904–917.
148. Bajpai Kim HR, Hou CT, et al. Bioconverted products of essential fatty acids as potential antimicrobial agents. N Biotechnol. 2009;26:122–130.
149. Pang T, Cardosa MJ, Guzman MG. Of cascades and perfect storms: the immunopathogenesis of dengue haemorrhagic fever-dengue shock syndrome (DHF/DSS). Immunol Cell Biol. 2007;85:43–45.
150. FAO/WHO. Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. In: FAO-WHO Experts. Probiotics in food. Cordoba, Argentina: FAO/WHO; 2001; p. 1–34.
151. Liderot K, Ahl M, Ozenci V., Secondary bacterial infections in patients with seasonal influenza A and pandemic H1N1. Biomed Res Int. 2013;2013:e376219.
152. Skalickova S, Heger Z, Krejcova L, et al. Perspective of use of antiviral peptides against influenza virus. Viruses. 2015;7:5428–5442.
153. Smit JM, Moesker B, Rodenhuis-Zybert I, et al. Flavivirus cell entry and membrane fusion. Viruses. 2011;3:160–171.
154. Chen L, Liu Y, Wang S, et al. Antiviral activity of peptide inhibitors derived from the protein E stem against Japanese encephalitis and Zika viruses. Antiviral Res. 2017;141:140–149.
155. Cruz-Oliveira C, Freire JM, Conceição TM, et al. Receptors and routes of dengue virus entry into the host cells. FEMS Microbiol Rev. 2015;39:155–170.
156. Alhoot MA, Rathinam AK, Wang SM, et al. Inhibition of dengue virus entry into target cells using synthetic antiviral peptides. Int J Med Sci. 2013;10:719–729.
157. Schmidt AG, Yang PL, Harrison SC., Peptide inhibitors of dengue-virus entry target a late-stage fusion intermediate. PLoS Pathog. 2010;6:e1000851.
158. Marcos JF, Gandia M., Antimicrobial peptides: to membranes and beyond. Expert Opin Drug Discov. 2009;4:659–671.
159. Rajendran L, Knoelker HJ, Simons K., Subcellular targeting strategies for drug design and delivery. Nat Rev Drug Discov. 2010;9:29–42.